From Trial to Practice: Integrating Amivantamab/Lazertinib in Advanced NSCLC

EP: 1.Clinical Case: EGFR-Mutant (Exon 19 del) Advanced NSCLC

EP: 2.The Treatment Landscape For Advanced EGFR-Mutant NSCLC

EP: 3.Emerging Insights From MARIPOSA: OS Updates From Amivantamab/Lazertinib in Advanced NSCLC

EP: 4.Navigating CNS Disease in EGFR-Mutant NSCLC

Now Viewing

EP: 5.From Trial to Practice: Integrating Amivantamab/Lazertinib in Advanced NSCLC

EP: 6.Patient Education and IRR Prophylaxis in Practice With Amivantamab/Lazertinib

Video content above is prompted by the following:

Real-world implementation of amivantamab plus lazertinib combination therapy has demonstrated outcomes consistent with clinical trial results, with practitioners reporting remarkable responses across various clinical settings. Experience from both clinical trials and compassionate use programs has shown the regimen's effectiveness not only in the frontline setting but also in challenging scenarios such as patients with leptomeningeal disease, where responses have been observed lasting over 10 months. This real-world evidence supports the trial data and provides confidence in the regimen's broad applicability.

The learning curve associated with amivantamab administration has proven manageable, with most practitioners developing comfort and expertise over time. Initial concerns about infusion reactions and complex adverse effect management have been addressed through standardized prophylactic protocols and accumulated clinical experience. The comparison to early immunotherapy adoption is apt, as both required initial learning periods for optimal toxicity management, but both ultimately became standard-of-care treatments with established management strategies.

Key success factors for implementing amivantamab plus lazertinib include comprehensive patient education, proactive adverse effect management, and demonstration of treatment efficacy to maintain patient confidence and adherence. Practitioners emphasize the importance of setting appropriate expectations while providing reassurance about manageable adverse effects. The development of standardized infusion reaction prophylaxis protocols, including dexamethasone premedication and graduated infusion rates, has significantly reduced the severity and frequency of infusion-related reactions. Most importantly, consistent demonstration of treatment effectiveness through imaging responses and symptom improvement helps maintain patient motivation and treatment compliance throughout the therapy course.